CA
NZ
UK
AU
IND
US
Twist Bioscience delivered notable top‑line growth, with therapeutics revenue climbing 55% and its DNA synthesis and protein solutions segment up 28% YoY. The company also highlighted a gross margin that now exceeds 50% and projected adjusted EBITDA to break even in the fourth quarter …
Johnson & Johnson’s stock edged higher in premarket trading as analysts weighed the healthcare company’s underlying strengths against potential overconfidence in its outlook. The movement underscores investor focus on the balance between solid fundamentals and market expectations, particularly in a sector sensitive to both …
Spruce Biosciences has taken a significant step toward addressing a critical gap in rare disease treatment, potentially becoming the first company to develop an enzyme replacement therapy for MPS IIIB. The development marks a pivotal moment for patients with mucopolysaccharidosis type IIIB, a debilitating …
The update, posted to the company’s website on July 8, 2026, marks a potential step forward in addressing a common and debilitating side effect of cancer immunotherapies.
United Therapeutics Corporation announced the completion of a cash purchase of privately held Thymmune Therapeutics for $140 million, adding a pipeline of regenerative thymic cell therapies to its existing portfolio. The agreement also contains an earn‑out provision that could raise total consideration by as …
Online platforms are issuing GLP-1 weight-loss prescriptions in under five minutes, bypassing traditional medical safeguards and drawing scrutiny from healthcare experts. The rapid approval process, often lacking in-person evaluations, has raised alarms about patient safety, improper dosing, and insufficient monitoring of side effects. Investors …
AETHLON MEDICAL Inc. (NASDAQ: AEMD) disclosed that its recent financing closed on July 7, 2026. The transaction combined the sale of common stock and associated warrants at a unified price of $0.71 per share, generating gross proceeds of about $4,000,000 million before fees.
XWELL Inc. Has entered into a definitive agreement to sell its XpresSpa Holdings and XpresTest units to Express Wellness Group, an affiliate of Face Haus, for $13 million. This move is part of the company’s broader effort to optimize its business structure, reduce operational …
Lifeward Ltd. (NASDAQ: LFWD) has finalized a structured financing deal, issuing convertible notes and warrants to accredited investors. The transaction, led by Oramed Pharmaceuticals Inc. As collateral agent, provides immediate capital while tying future funding to performance milestones.
Great Southern Copper (NASDAQ: GSBC) has completed its initial reverse circulation (RC) drilling program at the Especularita copper project in Chile, uncovering early signs of porphyry-style mineralisation. The results mark a key milestone for the company’s exploration efforts in a region known for high-grade …
Please wait processing your request...